227 related articles for article (PubMed ID: 22345386)
1. In vitro susceptibilities of clinical isolates of ertapenem-non-susceptible Enterobacteriaceae to cefotaxime, ceftazidime, cefepime and aztreonam.
Cheng NC; Liu CY; Huang YT; Liao CH; Teng LJ; Hsueh PR
J Antimicrob Chemother; 2012 Jun; 67(6):1413-21. PubMed ID: 22345386
[TBL] [Abstract][Full Text] [Related]
2. Comparison of European Committee on Antimicrobial Susceptibility Testing (EUCAST) and CLSI screening parameters for the detection of extended-spectrum β-lactamase production in clinical Enterobacteriaceae isolates.
Polsfuss S; Bloemberg GV; Giger J; Meyer V; Hombach M
J Antimicrob Chemother; 2012 Jan; 67(1):159-66. PubMed ID: 21972269
[TBL] [Abstract][Full Text] [Related]
3. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility profiles of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria.
Chen YH; Hsueh PR; Badal RE; Hawser SP; Hoban DJ; Bouchillon SK; Ni Y; Paterson DL
J Infect; 2011 Apr; 62(4):280-91. PubMed ID: 21382411
[TBL] [Abstract][Full Text] [Related]
5. Consequences of revised CLSI and EUCAST guidelines for antibiotic susceptibility patterns of ESBL- and AmpC β-lactamase-producing clinical Enterobacteriaceae isolates.
Hombach M; Mouttet B; Bloemberg GV
J Antimicrob Chemother; 2013 Sep; 68(9):2092-8. PubMed ID: 23633681
[TBL] [Abstract][Full Text] [Related]
6. Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia-Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002-2010.
Huang CC; Chen YS; Toh HS; Lee YL; Liu YM; Ho CM; Lu PL; Liu CE; Chen YH; Wang JH; Tang HJ; Yu KW; Liu YC; Chuang YC; Xu Y; Ni Y; Ko WC; Hsueh PR
Int J Antimicrob Agents; 2012 Jun; 40 Suppl():S4-10. PubMed ID: 22749058
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
Jang W; Park YJ; Park KG; Yu J
J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
[TBL] [Abstract][Full Text] [Related]
8. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
[TBL] [Abstract][Full Text] [Related]
9. Antimicrobial resistance to cefotaxime and ertapenem in Enterobacteriaceae: the effects of altering clinical breakpoints.
Liu PY; Shi ZY; Tung KC; Shyu CL; Chan KW; Liu JW; Wu ZY; Kao CC; Huang YC; Lin CF
J Infect Dev Ctries; 2014 Mar; 8(3):289-96. PubMed ID: 24619258
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of tigecycline against clinical isolates of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae.
Ku YH; Chuang YC; Yu WL
J Microbiol Immunol Infect; 2008 Aug; 41(4):332-6. PubMed ID: 18787741
[TBL] [Abstract][Full Text] [Related]
11. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of extended-spectrum beta-lactamases and its correlation with clinical laboratory standards institute interpretive criteria for disk diffusion susceptibility testing in enterobacteriaceae isolates in Thaialnd.
Tangkoskul T; Tiengrim S; Onsomang S; Pati N; Aswapokee N; Thamlikitkul V; Chayakulkeeree M
Southeast Asian J Trop Med Public Health; 2012 Nov; 43(6):1461-9. PubMed ID: 23413710
[TBL] [Abstract][Full Text] [Related]
13. Reevaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for 9 beta-lactams: adjustments of breakpoints for strains producing extended spectrum beta-lactamases.
Jones RN; Craig WA; Ambrose PG; Dudley MN; Pottumarthy S
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):235-46. PubMed ID: 16105568
[TBL] [Abstract][Full Text] [Related]
14. Carbapenem susceptibility among Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae isolates obtained from patients in intensive care units in Taiwan in 2005, 2007, and 2009.
Jean SS; Lee WS; Bai KJ; Yu KW; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
Diagn Microbiol Infect Dis; 2015 Apr; 81(4):290-5. PubMed ID: 25600841
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of multidrug-resistant Enterobacteriaceae clinical isolates to tigecycline.
Huang TD; Berhin C; Bogaerts P; Glupczynski Y
J Antimicrob Chemother; 2012 Nov; 67(11):2696-9. PubMed ID: 22833638
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
17. Susceptibility testing accuracy of a CTX-M-type extended-spectrum beta-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 beta-lactams.
Pottumarthy S; Yu Y; Sader HS; Jones RN; Chen M
Diagn Microbiol Infect Dis; 2005 Oct; 53(2):131-41. PubMed ID: 15939566
[TBL] [Abstract][Full Text] [Related]
18. Screening extended-spectrum beta-lactamase production in Enterobacter cloacae and Serratia marcescens using antibiogram-based methods.
Su PA; Wu LT; Cheng KC; Ko WC; Chuang YC; Yu WL
J Microbiol Immunol Infect; 2010 Feb; 43(1):26-34. PubMed ID: 20434120
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.
Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D
J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168
[TBL] [Abstract][Full Text] [Related]
20. Beta-lactam susceptibilities and prevalence of ESBL-producing isolates among more than 5000 European Enterobacteriaceae isolates.
Nijssen S; Florijn A; Bonten MJ; Schmitz FJ; Verhoef J; Fluit AC
Int J Antimicrob Agents; 2004 Dec; 24(6):585-91. PubMed ID: 15555882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
